MARKET

TTPH

TTPH

Tetraphase
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.460
-0.100
-3.91%
Closed 16:00 07/02 EDT
OPEN
2.540
PREV CLOSE
2.560
HIGH
2.560
LOW
2.400
VOLUME
228.15K
TURNOVER
--
52 WEEK HIGH
10.60
52 WEEK LOW
0.5600
MARKET CAP
17.87M
P/E (TTM)
-0.1330
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TTPH stock price target is 1.500 with a high estimate of 1.500 and a low estimate of 1.500.

EPS

TTPH News

More
Merger Arbitrage Mondays - Tetraphase Pharmaceuticals Finds A New Home
Seeking Alpha - Article · 5d ago
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
Benzinga · 06/25 13:26
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24)
Benzinga · 06/25 12:26
La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.
GlobeNewswire · 06/24 12:30
La Jolla to acquire Tetraphase Pharma
Seeking Alpha - Article · 06/24 11:53
Tetraphase Terminated Deal With Melinta
Benzinga · 06/24 11:38
UPDATE: Total Value Of La Jolla Purchase Of Tetraphase $43M In Upfront Cash Plus Potential Future Cash Payments Of Up To $16M
Benzinga · 06/24 11:33
UPDATE: Tetraphase Shareholders Will Be Entitled To Receive 1 Non-Tradeable Contingent Value Right
Tetraphase equity holders would also be entitled to receive, for each share of Tetraphase common stock, one non-tradeable CVR. The holders of the CVRs would be entitled to receive payments of up to an additional $16.0
Benzinga · 06/24 11:32

Industry

Pharmaceuticals
+0.58%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About TTPH

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
More

Webull offers kinds of Tetraphase Pharmaceuticals Inc stock information, including NASDAQ:TTPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TTPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TTPH stock methods without spending real money on the virtual paper trading platform.